FAMILY WEALTH REPORT | Pushing Innovation In Male Health After Decades Of Stagnation
ORIGINALLY POSTED ON: FAMILY WEALTH REPORT
Investment in medical/health issues is a long-term proposition. We talk to those making a health treatment focused on male contraception.
Dr Darlene Walley, CEO of NEXT Life Sciences, the maker of the male contraceptive product Plan A™ is on something of a mission. The firm is developing a “hydrogel” called Vasalgel®
This filters sperm from the vas deferens while allowing fluids to pass. The product, according to the Plan A™ website, is designed to provide contraception for more than 10 years and can be administered in a medical office setting with the option for reversal on demand.
There’s a lot at stake.
“More than 20 per cent of women cannot deal with oral contraceptives,” Dr. Darlene Walley said. “People want something that is safe and reliable.”
“There literally has not been an innovation in male contraception in decades, in some people’s lifetimes,” Dr Walley told Family Wealth Report. “This area is vastly overdue for innovation and we look forward to a world where there are non-hormonal, easily reversible options available for men so they can more actively participate in family planning and reproductive autonomy.”